Question 1

Is a natriuretic peptide protective, or only a sign of strain?

Accepted Answer

Both ideas appear in these sources, and the protective one rests on the thinnest ground. A 2012 Russian review of published data lists the triggers of ischemic heart postconditioning, including adenosine, opioids, nitric oxide and reactive oxygen species. Postconditioning is the protection a heart gains from brief, controlled interruptions of blood flow just after a blocked artery is reopened. The review then states that B-type natriuretic peptide is among the substances that can mimic postconditioning phenomenon, alongside insulin and carbon monoxide. The summary does not say in what model, and the company BNP keeps on that list, from insulin to carbon monoxide, shows it is a list of substances that act on one pathway rather than candidate therapies. So the protective role is a laboratory observation. It does not establish that a person with a high reading gains any shield from it, or that more would help.

Question 2

What did the largest nesiritide trial find?

Accepted Answer

It found a small edge on breathlessness that did not clear its own statistical bar, and no change in what happened over the following month. ASCEND-HF set two main outcomes: breathlessness at 6 and 24 hours, scored on a 7-point scale, and readmission for heart failure or death within 30 days. More patients on nesiritide reported markedly or moderately improved dyspnea at 6 hours, 44.5% against 42.1% on placebo, and at 24 hours, 68.2% against 66.1%. Dyspnea is breathlessness. Those gaps did not meet the prespecified level for significance, which is the threshold fixed before the trial began. Readmission or death within 30 days ran at 9.4% in the nesiritide group versus 10.1% in the placebo group, a difference compatible with chance. The authors summed it up as a small, nonsignificant effect on dyspnea when used in combination with other therapies. A gap of about two percentage points, in patients already getting standard care, is the size of benefit this trial supports.

Question 3

What did the earlier nesiritide trials measure?

Accepted Answer

Mostly pressures and symptoms over hours, which is where nesiritide looked strongest. VMAC took patients in hospital with heart failure that had suddenly worsened. Wedge pressure, a catheter reading of how far fluid is backing up toward the lungs, fell by 5.8 mm Hg at 3 hours on nesiritide. It fell by 3.8 on nitroglycerin and by 2 on placebo. More patients on nesiritide than on placebo said their breathing was easier at 3 hours, while nitroglycerin did not beat placebo. Deaths at six months did not differ between nesiritide and nitroglycerin. Before approval, nesiritide had been tested in 10 trials with 941 patients. A 2003 critique argued that in VMAC the efficacy and safety are actually more similar than dissimilar to those of nitroglycerin. A faster fall in a pressure is a real measurement, and it is a short-term one.

Question 4

Did nesiritide help the kidneys or increase urine output?

Accepted Answer

It was hoped to, and the trials that looked mostly did not find it. ROSE-AHF was built to test whether low-dose nesiritide or dopamine could protect the kidneys in heart failure with kidney problems. Its patients got dopamine, nesiritide or placebo for 72 hours on top of fluid-clearing care. Its main result is not given in the summaries among these sources. A 2009 systematic review was plainer: nesiritide did not improve kidney function in heart failure patients with mild kidney disease. After heart valve surgery, a small pilot trial found no extra urine with nesiritide in patients already on a set diuretic plan. Urine output was 1.33 mL/kg/hour with nesiritide and 1.68 with placebo. In 26 children with heart defects, creatinine fell during the drips, but each child was compared only with their own state before it began.

Question 5

Did nesiritide do better than dobutamine?

Accepted Answer

Against dobutamine, a medicine that makes the heart pump harder, nesiritide came out ahead, though on weaker designs than ASCEND-HF. A 2017 pooled analysis of 6 cohort studies found more patients survived on nesiritide, at an odds ratio of 1.97. Cohort studies follow patients given one medicine or the other by their own doctors, so sicker patients may have been steered toward one of them. In another trial, deaths at six months were lower with the lower of two nesiritide doses than with dobutamine. A 2003 review warns that deaths were not a planned end point there, so the result needs caution. A 2003 cost model built on pooled trial data found that the price of nesiritide was fully offset by lower hospital costs. Against that, a 2003 critique put nesiritide at about 40 times the price of standard agents such as nitroglycerin. Cost and benefit were argued over from the start.

Question 6

What did carperitide achieve in heart failure?

Accepted Answer

Carperitide, an A-type natriuretic peptide used mainly in Japan, showed no gain on the outcomes that matter after a patient goes home. The 2025 meta-analysis found no significant differences between the carperitide and comparison groups in long-term mortality, rehospitalization for heart failure or length of hospital stay. Its overall verdict was that carperitide may not be better than other care at cutting deaths in hospital or at helping people over the long run. No difference in how often people came back to hospital, or how long they stayed, is a real finding, because those are things a patient feels. A drip that eases fluid in the moment but does not change the months that follow is not the same as a lasting gain. The higher pooled death rate in hospital, and why the randomised trials alone did not confirm it, is covered on the Natriuretic peptide safety page.

Question 7

What happens when the body's own BNP is kept from breaking down?

Accepted Answer

This is the indirect way to raise a natriuretic peptide, as against a nesiritide drip, and its benefits are real but cannot be pinned on BNP alone. A 2018 review describes the prevention of BNP degradation by angiotensin receptor/neprilysin inhibitors, a class of heart failure medicine. In the 2026 PRAISE-MR trial of 84 patients, sacubitril/valsartan improved peak oxygen use during exercise by a mean change of +0.9 versus -0.6 mL/kg/min against standard care at 6 months. The same trial reported a median increase in a heart failure quality-of-life score of 10 versus 2 points. Peak oxygen use is a measure of how hard someone can exercise. Those patients took a medicine that both slows BNP breakdown and blocks a blood-pressure hormone, so the trial measured the medicine and did not separate out what BNP itself contributed.

Question 8

Does a falling reading mean a treatment worked?

Accepted Answer

Not by itself, and two of these trials show why. In the 2019 levosimendan meta-analysis of 132 patients given the drip and 125 controls, levosimendan was associated with a significantly reduced BNP level. Yet heart pumping improved only when patients were compared after versus before use, but not compared to controls. In HARP-III, sacubitril/valsartan had similar effects on kidney function and albuminuria to irbesartan over 12 months, even as it lowered cardiac markers. A reading that falls tells you the heart is under less strain at that moment. It does not tell you the outcome a trial was designed around has improved, and in both of these it had not, against a proper comparison.

Question 9

Does measuring it lead to better care?

Accepted Answer

Partly, and the answer depends on the setting. A 2014 Indian consensus document argued that these markers are feasible options against the present expensive measurements and may provide clinical benefits. Its point is cost: a blood test is cheaper than the imaging it can sometimes stand in for. A 2018 systematic review of bedside testing in primary care found the evidence limited, but noted that some studies show better results, especially when a POCT is combined with a clinical decision rule, a POCT being a test run at the bedside. A clinical decision rule is a written checklist that combines symptoms, examination and test results. The benefit there came from the reading inside a structured judgement, rather than from the number alone, and that is the pattern across these sources.

Question 10

Does the reading pick out who gains most from a treatment?

Accepted Answer

Trials use it to choose who enters, but picking individual winners has not worked well. A 2026 review in Circulation reports that subgroup analyses of neutral heart failure trials have failed to reliably identify responders to treatments. It notes instead that patients with obesity showed particularly large benefits when treated with effective drugs for heart failure with preserved ejection fraction. Preserved ejection fraction describes heart failure where the heart still pumps out a normal share of blood but is stiff and fills poorly. So body size has sorted responders better than any finer reading of the trial data, in that review's account. A natriuretic peptide figure decides who is eligible, and it has not been shown to decide who benefits.

Question 11

What else does the reading track?

Accepted Answer

Congestion beyond the heart, which shows the figure reports on the whole circulation backing up and not only on the heart muscle. A 2022 Japanese study of 51 heart failure patients and 10 healthy people measured liver stiffness with ultrasound, and found brain natriuretic peptide level correlated with the stiffness measure at r = 0.343. A correlation of 0.343 is modest: the two rise together, loosely. In the 18 inpatients followed through care, the stiffness reading fell from 2.01 to 1.62 m/seconds, which the authors read as congestion clearing. A congested liver stiffens because blood pools in it when the heart cannot keep up. A reading that moves with liver congestion is a reading of fluid load as much as of heart muscle, and that changes what a high figure is telling you.

Question 12

What has only been shown in animals?

Accepted Answer

In animal work, a natriuretic peptide is a readout that falls when a heart gets better. That is useful, and it is also easy to mistake for the cause. In a 2026 study, idebenone administration improved left ventricular ejection fraction in the heart failure animal model, while the same work tracked natriuretic peptides as signs of strain. Ejection fraction is the share of blood the main chamber pushes out with each beat. In rats bred to be sensitive to salt, a 2001 study found that two blood pressure medicines given together improved how the heart relaxed, and improved survival, more than either one alone. And in a 2014 rat study, finerenone cut heart muscle growth, the rats' brain natriuretic peptide and the protein in their urine more than eplerenone did. In each one, a medicine helped the rat heart and the natriuretic peptide figure followed it down. None of them gave a natriuretic peptide, so none of them shows what giving one would do.

Question 13

Which hoped-for benefits have never been measured?

Accepted Answer

Anything in a healthy body. None of the research behind this page gives a natriuretic peptide to a healthy person: the nesiritide and carperitide studies enrolled people with heart failure, heart disease or recent heart surgery. None measures weight, everyday blood pressure or exercise capacity after giving one outside hospital. The receptor imaging study among these sources is still recruiting, so even the step of seeing where these hormones bind in a living person has no posted result. That leaves any claimed benefit of a natriuretic peptide sold as a research compound unsupported by anything among the research behind this page. It is not evidence against any benefit. It is a question that has not been asked, which is a different situation from one that has been answered.

Question 14

Was there a trial large enough to settle the benefit?

Accepted Answer

For nesiritide there was, and that makes its record unusual among natriuretic peptides. A 2009 review described a continuing study expected to enroll 7000 patients by 2010, designed to clarify whether nesiritide reduces mortality, hospital length-of-stay and renal parameters. That study was ASCEND-HF, and on the hoped-for gains its answer was largely no. A 2012 review of heart transplant candidates set nesiritide among trials that were disappointing, against eplerenone and ivabradine. For carperitide, four randomised trials gave a result too wide to read, and no trial of that scale appears among these sources. That is not evidence that carperitide fails, only that its question is still open. The SPIRRIT-HFpEF design paper notes that conventional randomized controlled trials are complex and expensive, and builds its own trial inside a national heart failure registry instead. What the trials gave, and for how long, is laid out on the Natriuretic peptide dosage page.

Natriuretic peptide: what the research measured